Skip Navigation LinksHome > March 2014 - Volume 347 - Issue 3 > Lymphocyte-Platelet Crosstalk in Graves’ Disease
American Journal of the Medical Sciences:
doi: 10.1097/MAJ.0b013e3182831726
Clinical Investigation

Lymphocyte-Platelet Crosstalk in Graves’ Disease

Kuznik, Boris I. MD, PhD; Vitkovsky, Yuri A. MD, PhD; Gvozdeva, Olga V. MD; Solpov, Alexey V. MD, PhD; Magen, Eli MD

Collapse Box


Objective: Platelets can modulate lymphocytes’ role in the pathophysiology of thyroid autoimmune diseases. The present study was performed to clarify the status of platelet-lymphocyte subpopulations aggregation in circulating blood in patients with Graves’ disease (GD).

Methods: One hundred and fifty patients with GD (GD group) and 45 hyperthyroid patients with toxic multinodular goiter (TMG group) were recruited in the study. Control group consisted 150 healthy subjects. Immunophenotyping of lymphocytes was performed by flow cytometry. Detection of lymphocyte-platelet aggregates (LPAs) was done using light microscope after Ficoll-gradient centrifugation.

Results: The group of GD patients exhibited reduced CD8 lymphocyte and higher CD19 cell counts compared with TMG group and healthy controls. A greater number of activated CD3+, HLA-DR+ lymphocytes were observed in GD than in TMG group and control group. GD group was characterized by lower blood platelet count (232 ± 89 × 103 cells/µL) than TMG group (251 ± 97 × 103 cells/µL; P < 0.05) and control group (262 ± 95 × 103 cells/µL; P < 0.05). In GD group, more platelet-bound lymphocytes (332 ± 91 /µL) were found than that in TMG group (116 ± 67/µL, P < 0.005) and control group (104 ± 58 /µL; P < 0.001).

Conclusions: GD is associated with higher levels of activated lymphocytes and lymphocyte-platelet aggregates.

Copyright © 2014 by the Southern Society for Clinical Investigation.


Article Tools


Search for Similar Articles
You may search for similar articles that contain these same keywords or you may modify the keyword list to augment your search.